There's debate whether using PFS as a surrogate marker for OS is meaningful.
But if, as seen with Avastin, approval is gained on PFS alone, then perhaps the CAN-003 study may not need to wait for the secondary endpoints for approval.
My understanding was as below:
"The FDA has made it very clear that they will not approve drugs for ovarian cancer based upon PFS alone, and they are essentially demanding a difference in overall survival,”
- http://www.onclive.com/publications/oncology-live/2012/february-2012/Benefits-of-Bevacizumab-in-Ovarian-Cancer-Clarified/1
Yet, after 2 studies with no significant OS benefit and a 3rd with no OS data available, it's been approved.
- http://news.cancerconnect.com/avastin-delays-progression-of-ovarian-cancer-but-may-not-improve-overall-survival/
- Forums
- ASX - By Stock
- IMM
- success for avastin in europe
success for avastin in europe, page-21
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
40.5¢ | 40.5¢ | 39.5¢ | $998.2K | 2.495M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7607 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 36888 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7607 | 0.395 |
6 | 202444 | 0.390 |
4 | 118064 | 0.385 |
6 | 53762 | 0.380 |
1 | 8500 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 36888 | 3 |
0.405 | 151772 | 3 |
0.410 | 218559 | 6 |
0.415 | 230895 | 10 |
0.420 | 469144 | 7 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |